Stocks and Investing Stocks and Investing
Fri, May 5, 2023
Thu, May 4, 2023

Christopher Raymond Initiated (VRTX) at Buy and Held Target at $385 on, May 4th, 2023


Published on 2024-10-28 03:23:34 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $385 on, May 4th, 2023.

Christopher has made no other calls on VRTX in the last 4 months.



There are 19 other peers that have a rating on VRTX. Out of the 19 peers that are also analyzing VRTX, 6 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $305 on, Tuesday, May 2nd, 2023
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $340 on, Tuesday, May 2nd, 2023
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $315 on, Tuesday, May 2nd, 2023
  • Brian Skorney of "Baird" Maintained at Hold with Increased Target to $325 on, Tuesday, May 2nd, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Increased Target to $312 on, Wednesday, February 8th, 2023
  • Do Kim of "Piper Sandler" Maintained at Hold and Held Target at $296 on, Wednesday, February 8th, 2023


These are the ratings of the 13 analyists that currently disagree with Christopher


  • Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $400 on, Wednesday, May 3rd, 2023
  • William Pickering of "Bernstein" Maintained at Buy with Increased Target to $363 on, Wednesday, May 3rd, 2023
  • Jessica Fye of "JP Morgan" Maintained at Buy and Held Target at $345 on, Tuesday, May 2nd, 2023
  • Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $350 on, Tuesday, May 2nd, 2023
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $456 on, Tuesday, May 2nd, 2023
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $380 on, Tuesday, May 2nd, 2023
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $399 on, Tuesday, May 2nd, 2023
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $385 on, Tuesday, May 2nd, 2023
  • Evan Seigerman of "BMO Capital" Maintained at Buy and Held Target at $385 on, Tuesday, May 2nd, 2023
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $384 on, Tuesday, May 2nd, 2023
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $410 on, Tuesday, May 2nd, 2023
  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, March 29th, 2023
  • David Risinger of "SVB Leerink" Maintained at Buy with Decreased Target to $365 on, Wednesday, February 8th, 2023
Contributing Sources